CATALENT INC (CTLT)

US1488061029 - Common Stock

55.92  +0.12 (+0.22%)

After market: 55.92 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CTLT. CTLT was compared to 198 industry peers in the Pharmaceuticals industry. CTLT may be in some trouble as it scores bad on both profitability and health. CTLT is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

3

1. Profitability

1.1 Basic Checks

CTLT had negative earnings in the past year.
CTLT had a positive operating cash flow in the past year.
Of the past 5 years CTLT 4 years were profitable.
CTLT had a positive operating cash flow in each of the past 5 years.

1.2 Ratios

With a decent Return On Assets value of -13.04%, CTLT is doing good in the industry, outperforming 70.77% of the companies in the same industry.
With a decent Return On Equity value of -35.31%, CTLT is doing good in the industry, outperforming 62.56% of the companies in the same industry.
Industry RankSector Rank
ROA -13.04%
ROE -35.31%
ROIC N/A
ROA(3y)2.68%
ROA(5y)2.49%
ROE(3y)5.63%
ROE(5y)5.57%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

In the last couple of years the Operating Margin of CTLT has declined.
Looking at the Gross Margin, with a value of 17.94%, CTLT is in line with its industry, outperforming 48.72% of the companies in the same industry.
In the last couple of years the Gross Margin of CTLT has declined.
The Profit Margin and Operating Margin are not available for CTLT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 17.94%
OM growth 3Y-41.29%
OM growth 5Y-25.78%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.43%
GM growth 5Y-4.4%

More info and screens

2

2. Health

2.1 Basic Checks

CTLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
CTLT has more shares outstanding than it did 1 year ago.
CTLT has more shares outstanding than it did 5 years ago.
CTLT has a worse debt/assets ratio than last year.

2.2 Solvency

CTLT has an Altman-Z score of 1.37. This is a bad value and indicates that CTLT is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 1.37, CTLT is doing good in the industry, outperforming 64.10% of the companies in the same industry.
CTLT has a Debt/Equity ratio of 1.34. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of CTLT (1.34) is worse than 77.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF N/A
Altman-Z 1.37
ROIC/WACCN/A
WACC7.88%

2.3 Liquidity

A Current Ratio of 2.48 indicates that CTLT has no problem at all paying its short term obligations.
CTLT's Current ratio of 2.48 is in line compared to the rest of the industry. CTLT outperforms 40.51% of its industry peers.
CTLT has a Quick Ratio of 1.71. This is a normal value and indicates that CTLT is financially healthy and should not expect problems in meeting its short term obligations.
CTLT has a Quick ratio of 1.71. This is in the lower half of the industry: CTLT underperforms 65.64% of its industry peers.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 1.71

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CTLT have decreased strongly by -110.49% in the last year.
The earnings per share for CTLT have been decreasing by -10.31% on average. This is quite bad
Looking at the last year, CTLT shows a very negative growth in Revenue. The Revenue has decreased by -13.38% in the last year.
The Revenue has been growing by 11.59% on average over the past years. This is quite good.
EPS 1Y (TTM)-110.49%
EPS 3Y-21.77%
EPS 5Y-10.31%
EPS growth Q2Q-135.82%
Revenue 1Y (TTM)-13.38%
Revenue growth 3Y11.27%
Revenue growth 5Y11.59%
Revenue growth Q2Q-10.88%

3.2 Future

Based on estimates for the next years, CTLT will show a very strong growth in Earnings Per Share. The EPS will grow by 25.23% on average per year.
Based on estimates for the next years, CTLT will show a small growth in Revenue. The Revenue will grow by 6.55% on average per year.
EPS Next Y-53.32%
EPS Next 2Y23.38%
EPS Next 3Y28.25%
EPS Next 5Y25.23%
Revenue Next Year2.53%
Revenue Next 2Y4.73%
Revenue Next 3Y5.85%
Revenue Next 5Y6.55%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CTLT. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 36.37, CTLT can be considered very expensive at the moment.
78.97% of the companies in the same industry are more expensive than CTLT, based on the Price/Forward Earnings ratio.
CTLT's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.49.
Industry RankSector Rank
PE N/A
Fwd PE 36.37

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CTLT is valued a bit cheaper than 74.36% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 82.11

4.3 Compensation for Growth

A more expensive valuation may be justified as CTLT's earnings are expected to grow with 28.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.38%
EPS Next 3Y28.25%

More info and screens

0

5. Dividend

5.1 Amount

CTLT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CATALENT INC

NYSE:CTLT (4/26/2024, 7:04:01 PM)

After market: 55.92 0 (0%)

55.92

+0.12 (+0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap10.11B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 36.37
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.04%
ROE -35.31%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 17.94%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.48
Quick Ratio 1.71
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-110.49%
EPS 3Y-21.77%
EPS 5Y
EPS growth Q2Q
EPS Next Y-53.32%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-13.38%
Revenue growth 3Y11.27%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y